Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months in this group. Daniel Pollyea, MD, MS, shares results from this phase 1 study.
Recent Articles
MSKCC Researchers Correct Financial Disclosures
After reports from ProPublica and The New York Times revealed that scientists from Memorial Sloan Kettering Cancer Center (MSKCC) failed to disclose financial relationships...
Congress Passes Bills Banning Gag Clauses
Congress has passed two bills to ban “gag clauses” in contracts between pharmacies and insurance companies or pharmacy benefit managers (PBMs). The legislation, supported...
Justice Department Approves CVS-Aetna Merger
The U.S. Department of Justice (DOJ) has approved the merger of the pharmacy and health-care provider CVS Health with insurer Aetna, which would create...
FDA Approves DNA-Based Blood Compatibility Test
The U.S. Food and Drug Administration (FDA) has approved ID CORE XT, a molecular-based assay that can be used to determine blood donor and...
Clinical Trials of Leukemia and Lymphoma Drug Placed on Hold
Pharmaceutical manufacturer Affimed has halted two trials of its CD19/CD3-targeting T-cell engager AFM11 following reports of three serious adverse events (AEs), including one patient...
Current Issue
October 2018, Volume 4, Issue 12
This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.
